NBP Stock Analysis: Buy, Sell, or Hold?
$2.14
0.15 (7.54%)
▲
5d:
+33.75%
30d:
+25.15%
90d:
-13.01%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 02, 2026
0d
Get Alerted When NBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: NBP is 13.8% above its trading range ($1.88). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: NBP is 13.8% above its trading range ($1.88). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: NBP is currently trading at $2.14, which is considered extended relative to its 30-day fair value range of $1.51 to $1.88.
Technical Outlook: Technically, NBP is in a strong downtrend. The price is approaching resistance at $1.93. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+273.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NBP is in a strong downtrend. The price is approaching resistance at $1.93. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+273.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.51 -
$1.88
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+13.8% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.5%)
- BULLISH: Trading 273.8% below Wall St target ($8.00)
Trading Range Analysis
30-Day Trading Range
$1.51 -
$1.88
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.52
Resistance Level
$1.93
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.02
Wall Street Target
$8.00
(+273.8%)
Share & Embed Analysis
Last updated: July 02, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |